On May 2nd, 2012, Galecto Biotech AB announced that the company’s first financing round has been expanded and that two new investors, SEED Capital and Sunstone Capital, will join Novo A/S and Merck Serono Ventures in the company’s investor syndicate. The company will use the proceeds to advance its unique galectin modulators, which have the potential to treat a range of life threatening diseases.

In January 2012 Etteplan moved into their new offices at Ideon Science Park in Lund. “This is a strategic decision at a corporate level” says Anders Rosengren, Director.

BioInvent International AB (Bioinvent) and Les Laboratoires Servier (Servier) have entered into an antibody collaboration on an oncology target involved in tumour cell metabolism provided by Servier. BioInvent will receive a licensing fee, research support and potential milestone payments of more than EUR 11m, as well as royalty on future sales of the product.

Camurus enters exclusive collaboration, option and license agreement to its long acting octreotide product CAM2029 and the FluidCrystal® Injection depot technology.